Metformin-induced anticancer activities: recent insights
Authors:
- 27 June 2017
- journal article
- review article
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 399 (4) , 321-335
Abstract
Metformin is a widely used antidiabetic drug, and there is evidence among diabetic patients that metformin is a chemopreventive agent against multiple cancers. There is also evidence in human studies that metformin is a cancer chemotherapeutic agent, and several clinical trials that use metformin alone or in combination with other drugs are ongoing.In vivoandin vitrocancer cell culture studies demonstrate that metformin induces both AMPK-dependent and AMPK-independent genes/pathways that result in inhibition of cancer cell growth and migration and induction of apoptosis. The effects of metformin in cancer cells resemble the patterns observed after treatment with drugs that downregulate specificity protein 1 (Sp1), Sp3 and Sp4 or by knockdown of Sp1, Sp3 and Sp4 by RNA interference. Studies in pancreatic cancer cells clearly demonstrate that metformin decreases expression of Sp1, Sp3, Sp4 and pro-oncogenic Sp-regulated genes, demonstrating that one of the underlying mechanisms of action of metformin as an anticancer agent involves targeting of Sp transcription factors. These observations are consistent with metformin-mediated effects on genes/pathways in many other tumor types.Keywords
This publication has 177 references indexed in Scilit:
- Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cellsBMC Cancer, 2013
- Low Concentrations of Metformin Selectively Inhibit CD133+ Cell Proliferation in Pancreatic Cancer and Have Anticancer ActionPLOS ONE, 2013
- Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancerBritish Journal of Cancer, 2012
- Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancerCancer, 2011
- Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signalingProceedings of the National Academy of Sciences, 2010
- Inhibition of NFκB and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulationJournal of Biological Chemistry, 2010
- Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growthExperimental Cell Research, 2010
- AMP-activated Protein Kinase Antagonizes Pro-apoptotic Extracellular Signal-regulated Kinase Activation by Inducing Dual-specificity Protein Phosphatases in Response to Glucose Deprivation in HCT116 CarcinomaJournal of Biological Chemistry, 2010
- Antidiabetic Therapies Affect Risk of Pancreatic CancerGastroenterology, 2009
- Methyl succinate antagonises biguanide‐induced AMPK‐activation and death of pancreatic β‐cells through restoration of mitochondrial electron transferBritish Journal of Pharmacology, 2007